Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib

Ian H Gabriel, MD, David Marin, MD, FRCP, Shahzad Ahmad, Mr, Letizia Foroni, Hugues de Lavallade, MD, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Stephen O'Brien, PhD, Ruhena Sergeant, Dragana Milojkovic, MD, Marco Bua, Abdullah Alsuliman, Ahmad Khoder, Dr, Kate Stringaris, MD, MRCP, FRCPath, Nichola Cooper, MD, John M. Goldman, DM, FRCP, FRCPath, FMedSci, Jane F. Apperley, Katayoun Rezvani, MD, PhD

Blood (2010) 116 (21): 888.

https://doi.org/10.1182/blood.V116.21.888.888

Published: 2010

Journal Articles

Poor Adherence Is the Main Reason for Loss of CCyR and Imatinib Failure for CML Patients On Long Term Imatinib Therapy.

Amr R Ibrahim, Dragana Milojkovic, Marco Bua, Jamshid S Khorshad, Richard Szydlo, Lina Eliasson, Letizia Foroni, MD, PhD, Alistair Reid, Hugues de Lavallade, Katayoun Rezvani, MD, PhD, John M. Goldman, DM, FRCP, FRCPath, FMedSci, Jane Apperley, MBChB, FRCP, FRCPath, David Marin, MD, FRCP

Blood (2010) 116 (21): 3414.

https://doi.org/10.1182/blood.V116.21.3414.3414

Published: 2010

Journal Articles

Efficacy and Safety of Nilotinib In Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (Pts) with Type 2 Diabetes In the ENESTnd Trial.

Giuseppe Saglio, MD, PhD, Richard A. Larson, MD, Timothy P. Hughes, MD, MBBS, Surapol Issaragrisil, MD, Anna G. Turkina, MD, PhD, David Marin, MD, FRCP, Maria Zanichelli, MD, Hirohiko Shibayama, MD, PhD, Matt E. Kalaycio, MD, Francoise Rigal-Huguet, MD, Neil J. Gallagher, MD, PhD, Marcia Kayath, MD, Ming Zheng, PhD, Hagop Kantarjian, MD, Andreas Hochhaus, MD

Blood (2010) 116 (21): 3430.

https://doi.org/10.1182/blood.V116.21.3430.3430

Published: 2010

Journal Articles

Efficacy of Tyrosine Kinase Inhibitors (TKIs) as Third Line Therapy In Patients with Chronic Myeloid Leukaemia In Chronic Phase Who Have Failed Two Prior TKIs

Amr R Ibrahim, Marco Bua, Jamshid S Khorshad, Dragana Milojkovic, Lina Eliasson, Richard Szydlo, Letizia Foroni, MD, PhD, Alistair Reid, Hugues de Lavallade, Katayoun Rezvani, MD, PhD, John M. Goldman, DM, FRCP, FRCPath, FMedSci, Jane Apperley, MBChB, FRCP, FRCPath, David Marin, MD, FRCP

Blood (2010) 116 (21): 2274.

https://doi.org/10.1182/blood.V116.21.2274.2274

Published: 2010

Journal Articles

High Frequency and Cell Dose of Invariant NKT Cells In the Graft Are Associated with Lack of Clinically Significant Acute Gvhd In T Cell-Replete Sibling Allografts

Aristeidis Chaidos, MD, PhD, Richard M. Szydlo, Edward J. Kanfer, Francesco Dazzi, Donald H. MacDonald, David Marin, MD, FRCP, Dragana Milojkovic, Jiri Pavlu, John Davis, PhD, Katayoun Rezvani, MD, PhD, Amin Rahemtulla, MBBS, PhD, FRCP, Irene Roberts, MD, Jane F. Apperley, Anastasios Karadimitris

Blood (2010) 116 (21): 2539.

https://doi.org/10.1182/blood.V116.21.2539.2539

Published: 2010

NARROW

KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib

Poor Adherence Is the Main Reason for Loss of CCyR and Imatinib Failure for CML Patients On Long Term Imatinib Therapy.

Efficacy and Safety of Nilotinib In Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (Pts) with Type 2 Diabetes In the ENESTnd Trial.

Efficacy of Tyrosine Kinase Inhibitors (TKIs) as Third Line Therapy In Patients with Chronic Myeloid Leukaemia In Chronic Phase Who Have Failed Two Prior TKIs

High Frequency and Cell Dose of Invariant NKT Cells In the Graft Are Associated with Lack of Clinically Significant Acute Gvhd In T Cell-Replete Sibling Allografts

Email alerts

ASH Publications

American Society of Hematology

KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib

Poor Adherence Is the Main Reason for Loss of CCyR and Imatinib Failure for CML Patients On Long Term Imatinib Therapy.

Efficacy and Safety of Nilotinib In Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (Pts) with Type 2 Diabetes In the ENESTnd Trial.

Efficacy of Tyrosine Kinase Inhibitors (TKIs) as Third Line Therapy In Patients with Chronic Myeloid Leukaemia In Chronic Phase Who Have Failed Two Prior TKIs

High Frequency and Cell Dose of Invariant NKT Cells In the Graft Are Associated with Lack of Clinically Significant Acute Gvhd In T Cell-Replete Sibling Allografts

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only